open access
Simultaneous radiotherapy and radioimmunotherapy of malignant gliomas with anti-EGFR antibody labelled with iodine 125. Preliminary results
open access
Abstract
MATERIAL AND METHODS: Patients with anaplastic astrocytoma or primary glioblastoma were previously treated by a macroscopically radical neurosurgical approach and randomized either to radiotherapy + radioimmunotherapy arm or treated by radiotherapy alone. Seven patients were included in the group with radioimmunotherapy, among them five with GBM and two with AA, and five patients in the control arm. Patients were irradiated to 60 Gy using three-dimensional conformal noncoplanar techniques. Anti-EGFR 125I monoclonal antibody 425 radioimmunotherapy (50 mCi/course) was started during 4th week of radiotherapy and was repeated three times in one week intervals.
RESULTS: Time of follow-up ranges between 2 and 10 months in the anti-EGFR 125I radioimmunotherapy arm and 4 and 9 months in the control arm. Recurrence was diagnosed in all patients in the EGFR 125I group with a lethal outcome in two of them and in 4 patients in the control group. Median time to recurrence was 2 and 5 months respectively.
CONCLUSIONS: Taking into account early recurrences observed, we propose to continue the studies on the efficacy of adjuvant anti-EGFR 125I radioimmunotherapy in a selected group of patients in whom the greatest benefit may be expected on the basis of molecular studies, among them EGFR expression investigation.
Abstract
MATERIAL AND METHODS: Patients with anaplastic astrocytoma or primary glioblastoma were previously treated by a macroscopically radical neurosurgical approach and randomized either to radiotherapy + radioimmunotherapy arm or treated by radiotherapy alone. Seven patients were included in the group with radioimmunotherapy, among them five with GBM and two with AA, and five patients in the control arm. Patients were irradiated to 60 Gy using three-dimensional conformal noncoplanar techniques. Anti-EGFR 125I monoclonal antibody 425 radioimmunotherapy (50 mCi/course) was started during 4th week of radiotherapy and was repeated three times in one week intervals.
RESULTS: Time of follow-up ranges between 2 and 10 months in the anti-EGFR 125I radioimmunotherapy arm and 4 and 9 months in the control arm. Recurrence was diagnosed in all patients in the EGFR 125I group with a lethal outcome in two of them and in 4 patients in the control group. Median time to recurrence was 2 and 5 months respectively.
CONCLUSIONS: Taking into account early recurrences observed, we propose to continue the studies on the efficacy of adjuvant anti-EGFR 125I radioimmunotherapy in a selected group of patients in whom the greatest benefit may be expected on the basis of molecular studies, among them EGFR expression investigation.
Keywords
radioimmunotherapy; monoclonal antibody 425; epidermal growth factor receptor; iodine 125; glioblastoma; anaplastic astrocytoma
About this articleTitle
Simultaneous radiotherapy and radioimmunotherapy of malignant gliomas with anti-EGFR antibody labelled with iodine 125. Preliminary results
Journal
Issue
Pages
29-33
Published online
2002-01-17
Page views
723
Article views/downloads
1150
Bibliographic record
Nucl. Med. Rev 2002;5(1):29-33.
Keywords
radioimmunotherapy
monoclonal antibody 425
epidermal growth factor receptor
iodine 125
glioblastoma
anaplastic astrocytoma
Authors
Zbigniew Wygoda
Rafał Tarnawski
Luther Brady
Zenon Stęplewski
Piotr Bażowski
Maciej Wojtacha
Tomasz Stępień
Dorota Kula
Kszysztof Składowski
Danuta Kokocińska
Andrzej Wygoda
Agnieszka Pawlaczek
Aleksandra Etmańska
Dawid Larysz
Barbara Jarząb
